Clinical Trial Update: Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating irinotecan in combination with docetaxel for recurrent or metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED